Altimmune announces additional data from phase 2 NasoVAX study
Altimmune announced additional data from a Phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate. Data from this study demonstrated that 100% of the evaluated subjects remained seroprotected and the seroconversion rate was unchanged more than one year after vaccination. Subjects from the highest dose group of the study were invited to return as part of a study extension to evaluate the duration of immunity 1-year post-vaccination. Of 15 subjects invited, eight returned an average of 13.5 months after vaccination. Antibody titers for all 8 subjects remained seroprotective, with a median hemagglutination inhibition titer more than 3-times higher than generally accepted seroprotective levels. Coupled with previously demonstrated mucosal antibody and T-cell related correlates of immunoprotection, NasoVAX is well positioned to compete with other influenza vaccines currently under development.